Melanoma genome sequencing reveals frequent PREX2 mutations

By M. Berger, Eran Hodis, T. Heffernan, Y. L. Deribe, M. Lawrence, A. Protopopov, E. Ivanova, I. Watson, E. Nickerson, P. Ghosh and 38 more. Nature, 2012

752 citations recorded by the source corpus.

Melanoma is notable for its metastatic propensity, lethality in the advanced setting and association with ultraviolet exposure early in life. To obtain a comprehensive genomic view of melanoma in humans, we sequenced the genomes of 25 metastatic melanomas and matched germline DNA. A wide range of point mutation rates was observed: lowest in melanomas whose primaries arose on non-ultraviolet-exposed hairless skin of the extremities (3 and 14 per megabase (Mb) of genome), intermediate in those originating from hair-bearing skin of the trunk (5–55 per Mb), and highest in a patient with a documented history of chronic sun exposure (111 per Mb). Analysis of whole-genome sequence data identified PREX2 (phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2)—a PTEN-interacting protein and negative regulator of PTEN in breast cancer—as a significantly mutated gene with a mutation frequency of approximately 14% in an independent extension cohort of 107 human melanomas. PREX2 mutations are biologically relevant, as ectopic expression of mutant PREX2 accelerated tumour formation of immortalized human melanocytes in vivo. Thus, whole-genome sequencing of human melanoma tumours revealed genomic evidence of ultraviolet pathogenesis and discovered a new recurrently mutated gene in melanoma.

Subfields: Cell Biology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/6ed846842b065a52cbcceab92929afc2946aa3ef

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

Christopher Sander

In Molecular Biology

In Oncology

Citations in the corpus

A Landscape of Driver Mutations in Melanoma (2012, background): “The continuing discovery of recurrently mutated melanoma genes (Berger et al., 2012; Nikolaev et al., 2012; Stark et al., 2012; Wei et al., 2011) and the lack of identified driver mutations in the subtype without NRAS or BRAF mutation suggest that genetic understanding of this malignancy remains inc”
Genetic basis for clinical response to CTLA-4 blockade in melanoma. (2014, neutral): “Above normal 2 (18) 5 (36) 3 (12) 3 (21)”
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing (2012, result): “These validation rates generally meet or exceed those reported in similar sequencing studies (Banerji et al., 2012; Berger et al., 2012; Gerlinger et al., 2012; Nikolaev et al., 2012; Stransky et al., 2011; Cancer Genome Atlas Research Network, 2011; Totoki et al., 2011; Zang et al., 2012).”
Genomic Classification of Cutaneous Melanoma (2015, background): “Recent studies using next-generation sequencing (NGS) have identified additional genetic aberrations (Berger et al., 2012; Hodis et al., 2012; Krauthammer et al., 2012) that provide insights into the biological heterogeneity of melanoma and also have potentially important implications for prognosis…”
Signatures of mutational processes in human cancer (2013, neutral): “Others,forexamplesignatures14,15and21,showoverwhelming activityinasmallnumberofcancercases(SupplementaryFigs38,45 and56,respectively)andareperhapsmorelikelytobeduetocurrently uncharacterized defects in DNA maintenance.”
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden (2017, background): “We first looked in TCGA whole exome data from 50 melanoma patients and confirmed the somatic status of three of the mutations found in our cohort (chr7:6048723, chr7:6048760, and chr7:6048824) [62].”
Mutational heterogeneity in cancer and the search for new cancer genes (2013, neutral): “Analytical approaches in wide use today 1-9 , 13-16 13-16 identify as significantly mutated those genes harboring We therefore set out to study heterogeneity in mutation rates, in a data set of 3,083 tumor/ normal pairs across 27 tumor types, with 2,957 having whole-exome sequence and 126 having…”
Exome and whole genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity (2013, background): “The high frequency of AA transversions appears to be unique to EAC as equivalent events have not been identified in other cancer types 15–19, In total, A to C transversions at AA sites accounted for 29% of the total mutations (Fig.”
Oncotator: cancer variant annotation tool (2015, neutral): “…et al., 2011; Hammerman et al., 2011; Stransky et al., 2011; Wang et al., 2011; Banerji et al., 2012; Barbieri et al., 2012; Barretina et al., 2012; Berger et al., 2012; Hodis et al., 2012; Imielinski et al., 2012; Lee et al., 2012; Lohr et al., 2012; Pugh et al., 2012, 2013, 2014; Ciriello et…”
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency (2015, neutral): “had high numbers of somatic mutations as a result of exposure to cigarette smoke (lung cancers) or ultraviolet radiation (melanomas).(23,24) Our hypothesis was correct: the tumor of the single patient with colorectal cancer who had a response to PD-1 blockade was mismatch repair–deficient.”